ArticleChinese medicine2026
Interpretation of the efficacy-oriented components of decoction pieces in compounds based on the spectrum-effect relationship: Huangqin Qingfei decoction as an example.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute lung injury (ALI) is a severe respiratory inflammatory disorder with high morbidity and mortality. Huangqin Qingfei Decoction (HQQFD), a classic traditional Chinese medicine formulation composed of Scutellaria baicalensis Georgi (Scutellariae Radix, SR) and Gardenica jasminoides Ellis (Gardeniae Fructus, GF), is clinically used for treating respiratory inflammation including ALI. However, the pharmacodynamic basis of HQQFD and the optimal combination of raw and processed forms of SR and GF remain unclear. PURPOSE OF THE RESEARCH: This study aimed to evaluate the therapeutic differences among four clinical variants of HQQFD and identify key bioactive components using a lipopolysaccharide (LPS)-induced ALI rat model.
methodsALI rats were induced by LPS and treated with four HQQFD combinations (different raw/processed forms of SR and GF) at low or high doses. Therapeutic effects were assessed by lung histopathological observation, injury scoring, determination of inflammatory cytokine levels, lung wet/dry (W/D) ratio, and bronchoalveolar lavage fluid (BALF) analysis. Ultra-high performance liquid chromatography-Orbitrap high-resolution mass spectrometry (UHPLC-Orbitrap HRMS) was used to characterize the chemical profiles of different HQQFD variants. Pearson correlation analysis, gray relational analysis (GRA), and Orthogonal partial least squares (OPLS) spectrum-effect relationship analyses were performed to identify efficacy-oriented components.
resultsA total of 113 compounds were identified in HQQFD, among which 49 showed significant differences between raw and processed combinations. High-dose HQQFD groups exhibited superior therapeutic effects compared to low-dose groups, with the combination of wine Scutellariae Radix (WSR) and Gardeniae Fructus Praeparatus (GFP) being the most effective variant. This optimal combination significantly alleviated lung tissue damage, reduced inflammatory cytokine levels, improved lung W/D ratio, and attenuated BALF abnormalities in ALI rats. Spectrum-effect relationship analysis revealed 20 key bioactive components correlated with pharmacodynamic effects, in which 8 compounds include: geniposidic acid, genipin 1-gentiobioside, geniposide, baicalin, glychionide A, wogonoside, oroxylin A and crocetin was detected in lung tissues, these components are more closely related and may synergise more targets in the treatment of ALI.
conclusionThese findings demonstrate that HQQFD ameliorates LPS-induced ALI in rats by regulating the inflammatory response. The combination of WSR and GFP at high dose shows the best therapeutic effect, and the 20 identified compounds are potential pharmacodynamic substances of HQQFD. This study provides experimental evidence for the clinical optimization and quality control of HQQFD in the treatment of ALI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.